Abstract:Transforming growth factor-β (TGF-β), an important cytokine that plays a key role in many diseases regulates a wide array of cellular and physiologic processes via several TGF-β-driven signaling cascades, including the SMAD and non-SMAD-driven pathways. However, the detailed mechanisms by which TGF-β induces such diverse responses remain poorly understood. In particular, compared to the SMAD-dependent pathway, SMAD-independent pathways such as the ERK/MAPK pathway, which is critical in cancer progression, are less characterized. Here, we develop an integrated mechanistic model of the TGF-β-triggered ERK activation pathway and its crosstalk with the SMAD pathway, an analysis of which demonstrates how SMAD dynamics can be significantly modulated and regulated by the ERK pathway. In particular, SMAD-mediated transcription can be altered and delayed due to expedited phosphorylation of the linker of SMAD by TGF-β-activated ERK; and enhanced ERK activity, but attenuated SMAD activity, can be achieved simultaneously by fast turnover of TGF-β receptors via lipid-rafts. Also, in silico mutations of the TGF-β pathways reveal that the dynamic characteristics of both SMAD and ERK signaling may change significantly during cancer development. Specifically, normal cells may exhibit enhanced and sustained SMAD signaling with transient ERK activation, whereas cancerous cells may produce elevated and prolonged ERK signaling with enervated SMAD activation. These distinctive differences between normal and cancerous signaling behavior provide clues concerning, and potential explanations for, the seemingly contradictory roles played by TGF-β during cancer progression. We demonstrate how crosstalk among various branch pathways of TGF-β can influence overall cellular behavior. Based on model analysis, we hypothesize that aberrant molecular alterations drive changes in the intensity and duration of SMAD and ERK signaling during cancer progression and ultimately lead to an imbalance between the SMAD and ERK pathways in favor of tumor promotion. Thus, to treat cancer patients with a genetic signature of oncogenic Ras effectively may require at least a combination therapy to restore both the expression of TGF-β receptors and the GTPase activity of Ras.

TACE-Mediated Ectodomain Shedding of the Type I TGF-β Receptor Downregulates TGF-β Signaling

TACE-Mediated Ectodomain Shedding of the Type I TGF-b Receptor Downregulates TGF-b Signaling

TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association.

Direct Activation of TACE-Mediated Ectodomain Shedding by P38 MAP Kinase Regulates EGF Receptor-Dependent Cell Proliferation

Silencing TAK1 Alters Gene Expression Signatures in Bladder Cancer Cells

Sec3 Knockdown Inhibits TGF-β Induced Epithelial-Mesenchymal Transition Through the Down-Regulation of Akt Phosphorylation in A549 Cells.

The adhesion molecule PECAM-1 enhances the TGF-β-mediated inhibition of T cell function

Monoubiquitination of p120-catenin is essential for TGF-induced epithelial-mesenchymal transition and tumor metastasis

Optogenetic control of epithelial-mesenchymal transition in cancer cells

Computational Modeling and Analysis of the TGF-β-induced ERK and SMAD Pathways

The type III TGF-β receptor regulates epithelial and cancer cell migration through β-arrestin2-mediated activation of Cdc42

Calreticulin regulates TGF-β1-induced epithelial mesenchymal transition through modulating Smad signaling and calcium signaling.

ShcA Protects against Epithelial–Mesenchymal Transition through Compartmentalized Inhibition of TGF-β-Induced Smad Activation

Inhibition of ERK1/2 Signaling Impairs the Promoting Effects of TGF-β1 on Hepatocellular Carcinoma Cell Invasion and Epithelial-Mesenchymal Transition.

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells.

Downregulation of Transforming Growth Factor-Β Type II Receptor Prohibit Epithelial-to-mesenchymal Transition in Lens Epithelium.

TMEPAI inhibits TGF-β signaling by promoting lysosome degradation of TGF-β receptor and contributes to lung cancer development

Endocytic Regulation of TGF-β Signaling

Downregulation of cathepsin L suppresses cancer invasion and migration by inhibiting transforming growth factor‑β‑mediated epithelial‑mesenchymal transition.

TGF-β1 and TNF-α Synergistically Induce Epithelial to Mesenchymal Transition of Breast Cancer Cells by Enhancing TAK1 Activation

The Complex Interplay Between ERK1/2, TGFβ/Smad, and Jagged/Notch Signaling Pathways in the Regulation of Epithelial-Mesenchymal Transition in Retinal Pigment Epithelium Cells